TY  - CONF
AU  - Todorović, Lidija
AU  - Milovanović, Jelena
AU  - Mandušić, Vesna
AU  - Živaljević, Vladan
AU  - Paunović, Ivan
AU  - Stanojević, Boban
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12634
AB  - Background: Thyroid neoplasms include benign tumors – thyroid adenoma (TA), and malignant tumors of various histological types: papillary thyroid carcinoma (PTC) – the most common and usually indolent, anaplasƟ c thyroid carcinoma (ATC) – the most aggressive, and several other types such as follicular, medullary and poorly diff erenƟ ated. Despite the progress in understanding the epidemiology and geneƟ c landscape of thyroid tumors, the diagnosis, prognosis and treatment approach require further improvement. Interleukin-6 (IL-6) is a pro-infl ammatory cytokine with a central role in the regulaƟ on of immune and infl ammatory responses including autoimmune thyroid diseases. Studies have revealed a potenƟ al impact of IL-6 in the development, progression and control of thyroid cancer. The aim of this study was to provide novel aspects for the preoperaƟ ve diff erenƟ al diagnosis and/or prognosis of thyroid cancer. To achieve this, we assessed the circulaƟ ng levels of IL-6 in paƟ ents with benign and malignant thyroid tumors of various histotypes, compared them with healthy volunteers, and correlated the results with clinicopathological parameters. PaƟ ents and Methods: The study included 43 paƟ ents with benign or malignant thyroid tumors, surgically treated at the Center for Endocrine Surgery, Clinical Center of Serbia. IL-6 protein levels were determined in plasma samples by quanƟ taƟ ve ELISA. Parametric and nonparametric staƟ sƟ cal tests were used for data analysis. Results: IL-6 concentraƟ ons in paƟ ents with either TA or carcinoma (PTC, ATC) were signifi cantly higher compared to the healthy volunteers (Mann Whitney test). The highest concentraƟ ons were detected in ATC paƟ ents (Median±SD 15.97±0.71 pg/mL), being signifi cantly higher compared to TA and PTC (2.14±1.34 pg/mL and 1.96±2.12 pg/mL, respecƟ vely). In PTC microcarcinoma, IL-6 was higher compared to controls, but there was no signifi cant diff erence compared to other PTC or TA (Mann Whitney test). The correlaƟ on analysis with clinicopathological parameters in PTC paƟ ents revealed a trend towards the associaƟ on of increased IL-6 plasma levels with the presence of nodal and distant metastases. No other signifi cant associaƟ ons were found. Conclusion: PaƟ ents with thyroid adenoma or carcinoma have increased plasma IL-6 levels that are in proporƟ on with the aggressiveness of the thyroid tumor, suggesƟ ng that IL-6 might be a candidate biomarker for diagnosis and prognosis of thyroid neoplasms.
PB  - Belgrade : Serbian Association for Cancer Research
C3  - Oncology Insights
T1  - Interleukin-6, a potential plasma biomarker for diagnosis and prognosis of thyroid neoplasms
IS  - 1
SP  - 83
EP  - 83
UR  - https://hdl.handle.net/21.15107/rcub_vinar_12634
ER  - 

@conference{
author = "Todorović, Lidija and Milovanović, Jelena and Mandušić, Vesna and Živaljević, Vladan and Paunović, Ivan and Stanojević, Boban",
year = "2023",
abstract = "Background: Thyroid neoplasms include benign tumors – thyroid adenoma (TA), and malignant tumors of various histological types: papillary thyroid carcinoma (PTC) – the most common and usually indolent, anaplasƟ c thyroid carcinoma (ATC) – the most aggressive, and several other types such as follicular, medullary and poorly diff erenƟ ated. Despite the progress in understanding the epidemiology and geneƟ c landscape of thyroid tumors, the diagnosis, prognosis and treatment approach require further improvement. Interleukin-6 (IL-6) is a pro-infl ammatory cytokine with a central role in the regulaƟ on of immune and infl ammatory responses including autoimmune thyroid diseases. Studies have revealed a potenƟ al impact of IL-6 in the development, progression and control of thyroid cancer. The aim of this study was to provide novel aspects for the preoperaƟ ve diff erenƟ al diagnosis and/or prognosis of thyroid cancer. To achieve this, we assessed the circulaƟ ng levels of IL-6 in paƟ ents with benign and malignant thyroid tumors of various histotypes, compared them with healthy volunteers, and correlated the results with clinicopathological parameters. PaƟ ents and Methods: The study included 43 paƟ ents with benign or malignant thyroid tumors, surgically treated at the Center for Endocrine Surgery, Clinical Center of Serbia. IL-6 protein levels were determined in plasma samples by quanƟ taƟ ve ELISA. Parametric and nonparametric staƟ sƟ cal tests were used for data analysis. Results: IL-6 concentraƟ ons in paƟ ents with either TA or carcinoma (PTC, ATC) were signifi cantly higher compared to the healthy volunteers (Mann Whitney test). The highest concentraƟ ons were detected in ATC paƟ ents (Median±SD 15.97±0.71 pg/mL), being signifi cantly higher compared to TA and PTC (2.14±1.34 pg/mL and 1.96±2.12 pg/mL, respecƟ vely). In PTC microcarcinoma, IL-6 was higher compared to controls, but there was no signifi cant diff erence compared to other PTC or TA (Mann Whitney test). The correlaƟ on analysis with clinicopathological parameters in PTC paƟ ents revealed a trend towards the associaƟ on of increased IL-6 plasma levels with the presence of nodal and distant metastases. No other signifi cant associaƟ ons were found. Conclusion: PaƟ ents with thyroid adenoma or carcinoma have increased plasma IL-6 levels that are in proporƟ on with the aggressiveness of the thyroid tumor, suggesƟ ng that IL-6 might be a candidate biomarker for diagnosis and prognosis of thyroid neoplasms.",
publisher = "Belgrade : Serbian Association for Cancer Research",
journal = "Oncology Insights",
title = "Interleukin-6, a potential plasma biomarker for diagnosis and prognosis of thyroid neoplasms",
number = "1",
pages = "83-83",
url = "https://hdl.handle.net/21.15107/rcub_vinar_12634"
}

Todorović, L., Milovanović, J., Mandušić, V., Živaljević, V., Paunović, I.,& Stanojević, B.. (2023). Interleukin-6, a potential plasma biomarker for diagnosis and prognosis of thyroid neoplasms. in Oncology Insights
Belgrade : Serbian Association for Cancer Research.(1), 83-83.
https://hdl.handle.net/21.15107/rcub_vinar_12634

Todorović L, Milovanović J, Mandušić V, Živaljević V, Paunović I, Stanojević B. Interleukin-6, a potential plasma biomarker for diagnosis and prognosis of thyroid neoplasms. in Oncology Insights. 2023;(1):83-83.
https://hdl.handle.net/21.15107/rcub_vinar_12634 .

Todorović, Lidija, Milovanović, Jelena, Mandušić, Vesna, Živaljević, Vladan, Paunović, Ivan, Stanojević, Boban, "Interleukin-6, a potential plasma biomarker for diagnosis and prognosis of thyroid neoplasms" in Oncology Insights, no. 1 (2023):83-83,
https://hdl.handle.net/21.15107/rcub_vinar_12634 .

TY  - CONF
AU  - Kožik, Bojana
AU  - Božović, Ana
AU  - Kokanov, Nikola
AU  - Mandušić, Vesna
AU  - Živaljević, Vladan
AU  - Paunović, Ivan
AU  - Stanojević, Boban
AU  - Todorović, Lidija
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12507
AB  - Adrenocortical carcinoma (ACC) is a rare cancer with poor prognosis. Identifying novel molecular parameters with prognostic value is of great clinical importance for a personalized therapeutic approach. Epigenetic changes have been proven to play an important role in cancer pathogenesis. Hypermethylation of the promoter region of p16INK4a gene has been shown to be a significant event in a number of cancer types. Several studies suggested that it might have a prognostic impact in ACC as well, however the data are relatively ambiguous.  According to the dataset from The Cancer Genome Atlas (TCGA) database, in cohort of 79 ACC patients, the analysis of the p16INK4a gene methylation showed that higher methylation was associated with shorter progression-free and overall survival. We evaluate the methylation status of p16INK4a in a preliminary cohort of 30 ACC patients by using the methylation-specific polymerase chain reaction (MSP) and aberrant methylation of p16INK4a was present in 66.7% (20/30) of cases. Our results indicate that epigenetic alteration of this gene is common event in ACC and may be important for pathogenesis of this tumor type. Although, we did not observed significant association between p16INK4a methylation status and clinico-pathological characteristics (age and gender, tumor size and weight, regional lymph node and distant metastasis), we will evaluate methylation status of this gene in another 30 ACC cases and compare it with methylation profile of adrenocortical adenoma patients, since inactivation of p16INK4a gene by promoter hypermethylation has been frequently reported as an early event in premalignant lesions in many tumor types.
PB  - Poland : The National Institute of Cardiology
C3  - The 21st ENS@T and 1st COST-HARMONIS@TION meeting : Book of abstracts
T1  - Methylation status of p16INK4a tumor-suppressor gene in adrenocortical carcinoma: preliminary study
SP  - A17
UR  - https://hdl.handle.net/21.15107/rcub_vinar_12507
ER  - 

@conference{
author = "Kožik, Bojana and Božović, Ana and Kokanov, Nikola and Mandušić, Vesna and Živaljević, Vladan and Paunović, Ivan and Stanojević, Boban and Todorović, Lidija",
year = "2022",
abstract = "Adrenocortical carcinoma (ACC) is a rare cancer with poor prognosis. Identifying novel molecular parameters with prognostic value is of great clinical importance for a personalized therapeutic approach. Epigenetic changes have been proven to play an important role in cancer pathogenesis. Hypermethylation of the promoter region of p16INK4a gene has been shown to be a significant event in a number of cancer types. Several studies suggested that it might have a prognostic impact in ACC as well, however the data are relatively ambiguous.  According to the dataset from The Cancer Genome Atlas (TCGA) database, in cohort of 79 ACC patients, the analysis of the p16INK4a gene methylation showed that higher methylation was associated with shorter progression-free and overall survival. We evaluate the methylation status of p16INK4a in a preliminary cohort of 30 ACC patients by using the methylation-specific polymerase chain reaction (MSP) and aberrant methylation of p16INK4a was present in 66.7% (20/30) of cases. Our results indicate that epigenetic alteration of this gene is common event in ACC and may be important for pathogenesis of this tumor type. Although, we did not observed significant association between p16INK4a methylation status and clinico-pathological characteristics (age and gender, tumor size and weight, regional lymph node and distant metastasis), we will evaluate methylation status of this gene in another 30 ACC cases and compare it with methylation profile of adrenocortical adenoma patients, since inactivation of p16INK4a gene by promoter hypermethylation has been frequently reported as an early event in premalignant lesions in many tumor types.",
publisher = "Poland : The National Institute of Cardiology",
journal = "The 21st ENS@T and 1st COST-HARMONIS@TION meeting : Book of abstracts",
title = "Methylation status of p16INK4a tumor-suppressor gene in adrenocortical carcinoma: preliminary study",
pages = "A17",
url = "https://hdl.handle.net/21.15107/rcub_vinar_12507"
}

Kožik, B., Božović, A., Kokanov, N., Mandušić, V., Živaljević, V., Paunović, I., Stanojević, B.,& Todorović, L.. (2022). Methylation status of p16INK4a tumor-suppressor gene in adrenocortical carcinoma: preliminary study. in The 21st ENS@T and 1st COST-HARMONIS@TION meeting : Book of abstracts
Poland : The National Institute of Cardiology., A17.
https://hdl.handle.net/21.15107/rcub_vinar_12507

Kožik B, Božović A, Kokanov N, Mandušić V, Živaljević V, Paunović I, Stanojević B, Todorović L. Methylation status of p16INK4a tumor-suppressor gene in adrenocortical carcinoma: preliminary study. in The 21st ENS@T and 1st COST-HARMONIS@TION meeting : Book of abstracts. 2022;:A17.
https://hdl.handle.net/21.15107/rcub_vinar_12507 .

Kožik, Bojana, Božović, Ana, Kokanov, Nikola, Mandušić, Vesna, Živaljević, Vladan, Paunović, Ivan, Stanojević, Boban, Todorović, Lidija, "Methylation status of p16INK4a tumor-suppressor gene in adrenocortical carcinoma: preliminary study" in The 21st ENS@T and 1st COST-HARMONIS@TION meeting : Book of abstracts (2022):A17,
https://hdl.handle.net/21.15107/rcub_vinar_12507 .

TY  - CONF
AU  - Todorović, Lidija
AU  - Kožik, Bojana
AU  - Božović, Ana
AU  - Mandušić, Vesna
AU  - Stanojević, Boban
AU  - Živaljević, Vladan
AU  - Paunović, Ivan
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12509
AB  - Adrenocortical tumors (ACTs) are heterogeneous neoplasms with incompletely understood pathogenesis. Correct differential diagnosis between adrenocortical adenoma (ACA) and localized adrenocortical carcinoma (ACC), as well as improved prognostic stratification of ACC patients, are of great clinical importance. Alterations in gene expression patterns have been found in adrenocortical neoplasms compared to normal tissue. In addition to having a role in tumorigenesis, distinct gene expression signatures may help to distinguish different ACT types. The combined expression patterns of PINK1, DLGAP5 and BUB1B have been suggested as malignancy and outcome predictors in previous studies. In order to validate their diagnostic/prognostic potential, we investigated the expression levels of these three genes and their association with clinico-pathological parameters in a cohort of 47 ACC and 15 ACA patients from Serbia. In addition, we analyzed the association of their expression levels with survival data in an independent ACC cohort of 79 patients from The Cancer Genome Atlas (TCGA) database. The results showed that high expression levels of BUB1B and DLGAP5, and low expression levels of PINK1 significantly associated with ACC. Moreover, combined expression of both DLGAP5 and BUB1B with PINK1 were significantly higher in localized ACC compared with ACA. The results from the TCGA cohort showed that expression alterations of these genes were strong predictors of disease-free and overall survival in ACC patients. These results are consistent with the previously reported results and confirm that the expression patterns of PINK1, DLGAP5 and BUB1B might have value as molecular predictors of malignancy and/or survival in ACC patients.
PB  - Poland : The National Institute of Cardiology
C3  - The 21st ENS@T and 1st COST-HARMONIS@TION meeting : Book of abstracts
T1  - Validation of diagnostic and prognostic potential of PINK1, DLGAP5 and BUB1B expression patterns in adrenocortical tumors
SP  - A39
UR  - https://hdl.handle.net/21.15107/rcub_vinar_12509
ER  - 

@conference{
author = "Todorović, Lidija and Kožik, Bojana and Božović, Ana and Mandušić, Vesna and Stanojević, Boban and Živaljević, Vladan and Paunović, Ivan",
year = "2022",
abstract = "Adrenocortical tumors (ACTs) are heterogeneous neoplasms with incompletely understood pathogenesis. Correct differential diagnosis between adrenocortical adenoma (ACA) and localized adrenocortical carcinoma (ACC), as well as improved prognostic stratification of ACC patients, are of great clinical importance. Alterations in gene expression patterns have been found in adrenocortical neoplasms compared to normal tissue. In addition to having a role in tumorigenesis, distinct gene expression signatures may help to distinguish different ACT types. The combined expression patterns of PINK1, DLGAP5 and BUB1B have been suggested as malignancy and outcome predictors in previous studies. In order to validate their diagnostic/prognostic potential, we investigated the expression levels of these three genes and their association with clinico-pathological parameters in a cohort of 47 ACC and 15 ACA patients from Serbia. In addition, we analyzed the association of their expression levels with survival data in an independent ACC cohort of 79 patients from The Cancer Genome Atlas (TCGA) database. The results showed that high expression levels of BUB1B and DLGAP5, and low expression levels of PINK1 significantly associated with ACC. Moreover, combined expression of both DLGAP5 and BUB1B with PINK1 were significantly higher in localized ACC compared with ACA. The results from the TCGA cohort showed that expression alterations of these genes were strong predictors of disease-free and overall survival in ACC patients. These results are consistent with the previously reported results and confirm that the expression patterns of PINK1, DLGAP5 and BUB1B might have value as molecular predictors of malignancy and/or survival in ACC patients.",
publisher = "Poland : The National Institute of Cardiology",
journal = "The 21st ENS@T and 1st COST-HARMONIS@TION meeting : Book of abstracts",
title = "Validation of diagnostic and prognostic potential of PINK1, DLGAP5 and BUB1B expression patterns in adrenocortical tumors",
pages = "A39",
url = "https://hdl.handle.net/21.15107/rcub_vinar_12509"
}

Todorović, L., Kožik, B., Božović, A., Mandušić, V., Stanojević, B., Živaljević, V.,& Paunović, I.. (2022). Validation of diagnostic and prognostic potential of PINK1, DLGAP5 and BUB1B expression patterns in adrenocortical tumors. in The 21st ENS@T and 1st COST-HARMONIS@TION meeting : Book of abstracts
Poland : The National Institute of Cardiology., A39.
https://hdl.handle.net/21.15107/rcub_vinar_12509

Todorović L, Kožik B, Božović A, Mandušić V, Stanojević B, Živaljević V, Paunović I. Validation of diagnostic and prognostic potential of PINK1, DLGAP5 and BUB1B expression patterns in adrenocortical tumors. in The 21st ENS@T and 1st COST-HARMONIS@TION meeting : Book of abstracts. 2022;:A39.
https://hdl.handle.net/21.15107/rcub_vinar_12509 .

Todorović, Lidija, Kožik, Bojana, Božović, Ana, Mandušić, Vesna, Stanojević, Boban, Živaljević, Vladan, Paunović, Ivan, "Validation of diagnostic and prognostic potential of PINK1, DLGAP5 and BUB1B expression patterns in adrenocortical tumors" in The 21st ENS@T and 1st COST-HARMONIS@TION meeting : Book of abstracts (2022):A39,
https://hdl.handle.net/21.15107/rcub_vinar_12509 .

TY  - CONF
AU  - Todorović, Lidija
AU  - Petrović, Nina
AU  - Mandušić, Vesna
AU  - Živaljević, Vladan
AU  - Paunović, Ivan
AU  - Stanojević, Boban
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12426
AB  - Although one of the rarest known malignancies, with an estimated prevalence of 0.005% of all cancers, parathyroid carcinoma (PC) represents a clinical and therapeutic challenge. The identification of novel diagnostic biomarkers able to preoperatively distinguish among different parathyroid neoplastic types is of great clinical importance. However, there is a lack of both experimental and bioinformatics data in this field. In the present study, we examined the expression levels of two microRNAs frequently implicated in cancer, miR-30a-3p and miR-92a-3p, in 10 PC and 10 parathyroid adenoma (PA) tissues using reverse transcription quantitative (RT-qPCR). In addition, we analyzed their association with clinical and histopathological parameters. For statistical analysis we used non-parametric tests – Mann–Whitney U test and Spearman’s correlation test. Furthermore, by using several online tools such as miRNet, miRror Suit, and DisGeNET we analyzed combinatorial target genes of the two miRs and investigated their potential roles in parathyroid carcinoma and adenoma. The expression levels of both miR-30a-3p and miR-92a-3p were upregulated in PC compared to PA (p= 0.017 and p=0.0015 respectively). A positive correlation between their expression levels was identified both in PC (p=0.025, r=0.697) and PA (p=0.008, r=0745), indicating their combined action. There were no significant associations between the expression levels of these two miRs and clinicopathological characteristics in the PC group. According to the in silico analysis, the two miRs share a number of target genes, predominantly included in gene expression, cell cycle regulation, and several signalling pathways such as WNT/β catenin, which was found to be frequently aberrant in PC. Although their role and diagnostic utility remain to be elucidated, the data here reported suggest that miR-30a-3p and miR-92a-3p might be involved in parathyroid cancer pathogenesis and that they might be candidates for differential diagnosis between parathyroid carcinoma and adenoma.
C3  - 5th Annual Meeting STRATAGEM: New diagnostic and therapeutic tools against multidrug resistant tumours : Book of abstracts
T1  - miR-30a-3p and miR-92a-3p as potential diagnostic biomarkers in parathyroid carcinoma
UR  - https://hdl.handle.net/21.15107/rcub_vinar_12426
ER  - 

@conference{
author = "Todorović, Lidija and Petrović, Nina and Mandušić, Vesna and Živaljević, Vladan and Paunović, Ivan and Stanojević, Boban",
year = "2022",
abstract = "Although one of the rarest known malignancies, with an estimated prevalence of 0.005% of all cancers, parathyroid carcinoma (PC) represents a clinical and therapeutic challenge. The identification of novel diagnostic biomarkers able to preoperatively distinguish among different parathyroid neoplastic types is of great clinical importance. However, there is a lack of both experimental and bioinformatics data in this field. In the present study, we examined the expression levels of two microRNAs frequently implicated in cancer, miR-30a-3p and miR-92a-3p, in 10 PC and 10 parathyroid adenoma (PA) tissues using reverse transcription quantitative (RT-qPCR). In addition, we analyzed their association with clinical and histopathological parameters. For statistical analysis we used non-parametric tests – Mann–Whitney U test and Spearman’s correlation test. Furthermore, by using several online tools such as miRNet, miRror Suit, and DisGeNET we analyzed combinatorial target genes of the two miRs and investigated their potential roles in parathyroid carcinoma and adenoma. The expression levels of both miR-30a-3p and miR-92a-3p were upregulated in PC compared to PA (p= 0.017 and p=0.0015 respectively). A positive correlation between their expression levels was identified both in PC (p=0.025, r=0.697) and PA (p=0.008, r=0745), indicating their combined action. There were no significant associations between the expression levels of these two miRs and clinicopathological characteristics in the PC group. According to the in silico analysis, the two miRs share a number of target genes, predominantly included in gene expression, cell cycle regulation, and several signalling pathways such as WNT/β catenin, which was found to be frequently aberrant in PC. Although their role and diagnostic utility remain to be elucidated, the data here reported suggest that miR-30a-3p and miR-92a-3p might be involved in parathyroid cancer pathogenesis and that they might be candidates for differential diagnosis between parathyroid carcinoma and adenoma.",
journal = "5th Annual Meeting STRATAGEM: New diagnostic and therapeutic tools against multidrug resistant tumours : Book of abstracts",
title = "miR-30a-3p and miR-92a-3p as potential diagnostic biomarkers in parathyroid carcinoma",
url = "https://hdl.handle.net/21.15107/rcub_vinar_12426"
}

Todorović, L., Petrović, N., Mandušić, V., Živaljević, V., Paunović, I.,& Stanojević, B.. (2022). miR-30a-3p and miR-92a-3p as potential diagnostic biomarkers in parathyroid carcinoma. in 5th Annual Meeting STRATAGEM: New diagnostic and therapeutic tools against multidrug resistant tumours : Book of abstracts.
https://hdl.handle.net/21.15107/rcub_vinar_12426

Todorović L, Petrović N, Mandušić V, Živaljević V, Paunović I, Stanojević B. miR-30a-3p and miR-92a-3p as potential diagnostic biomarkers in parathyroid carcinoma. in 5th Annual Meeting STRATAGEM: New diagnostic and therapeutic tools against multidrug resistant tumours : Book of abstracts. 2022;.
https://hdl.handle.net/21.15107/rcub_vinar_12426 .

Todorović, Lidija, Petrović, Nina, Mandušić, Vesna, Živaljević, Vladan, Paunović, Ivan, Stanojević, Boban, "miR-30a-3p and miR-92a-3p as potential diagnostic biomarkers in parathyroid carcinoma" in 5th Annual Meeting STRATAGEM: New diagnostic and therapeutic tools against multidrug resistant tumours : Book of abstracts (2022),
https://hdl.handle.net/21.15107/rcub_vinar_12426 .

TY  - JOUR
AU  - Todorović, Lidija
AU  - Mandušić, Vesna
AU  - Vučetić-Tadić, Biljana
AU  - Živaljević, Vladan
AU  - Paunović, Ivan
AU  - Stanojević, Boban
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9055
AB  - A growing number of studies suggest a tumor suppressive role and potential prognostic significance of miR- 30a-3p in different types of cancer. However, relatively few studies have focused on this microRNA in neoplastic thyroid lesions, including papillary thyroid cancer (PTC). The aim of our study was to shed more light on the potential involvement and clinical relevance of miR-30a-3p in this type of cancer. We examined the expression levels of this microRNA in 42 pairs of PTCs and matched non-tumor thyroid tissues using quantitative RT-PCR. We analyzed their association with clinical and histopathological parameters. The results revealed that miR-30a-3p was significantly downregulated in the majority of PTC tissues compared to corresponding non-tumor tissues. Moreover, decreased expression of miR-30a-3p was associated with advanced clinical stage, presence of multiple tumor foci and capsular invasion, suggesting a role in aggressive disease. Although the role of this microRNA and its prognostic utility remain to be elucidated, the presented data suggest that downregulated expression of miR-30a-3p indicates poorer prognosis in PTC patients, warranting further investigations.
T2  - Archives of Biological Sciences
T1  - Altered expression of microRNA-30a-3p in papillary thyroid cancer and its association with clinicopathological characteristics
VL  - 72
IS  - 1
SP  - 31
EP  - 36
DO  - 10.2298/ABS191004063T
ER  - 

@article{
author = "Todorović, Lidija and Mandušić, Vesna and Vučetić-Tadić, Biljana and Živaljević, Vladan and Paunović, Ivan and Stanojević, Boban",
year = "2020",
abstract = "A growing number of studies suggest a tumor suppressive role and potential prognostic significance of miR- 30a-3p in different types of cancer. However, relatively few studies have focused on this microRNA in neoplastic thyroid lesions, including papillary thyroid cancer (PTC). The aim of our study was to shed more light on the potential involvement and clinical relevance of miR-30a-3p in this type of cancer. We examined the expression levels of this microRNA in 42 pairs of PTCs and matched non-tumor thyroid tissues using quantitative RT-PCR. We analyzed their association with clinical and histopathological parameters. The results revealed that miR-30a-3p was significantly downregulated in the majority of PTC tissues compared to corresponding non-tumor tissues. Moreover, decreased expression of miR-30a-3p was associated with advanced clinical stage, presence of multiple tumor foci and capsular invasion, suggesting a role in aggressive disease. Although the role of this microRNA and its prognostic utility remain to be elucidated, the presented data suggest that downregulated expression of miR-30a-3p indicates poorer prognosis in PTC patients, warranting further investigations.",
journal = "Archives of Biological Sciences",
title = "Altered expression of microRNA-30a-3p in papillary thyroid cancer and its association with clinicopathological characteristics",
volume = "72",
number = "1",
pages = "31-36",
doi = "10.2298/ABS191004063T"
}

Todorović, L., Mandušić, V., Vučetić-Tadić, B., Živaljević, V., Paunović, I.,& Stanojević, B.. (2020). Altered expression of microRNA-30a-3p in papillary thyroid cancer and its association with clinicopathological characteristics. in Archives of Biological Sciences, 72(1), 31-36.
https://doi.org/10.2298/ABS191004063T

Todorović L, Mandušić V, Vučetić-Tadić B, Živaljević V, Paunović I, Stanojević B. Altered expression of microRNA-30a-3p in papillary thyroid cancer and its association with clinicopathological characteristics. in Archives of Biological Sciences. 2020;72(1):31-36.
doi:10.2298/ABS191004063T .

Todorović, Lidija, Mandušić, Vesna, Vučetić-Tadić, Biljana, Živaljević, Vladan, Paunović, Ivan, Stanojević, Boban, "Altered expression of microRNA-30a-3p in papillary thyroid cancer and its association with clinicopathological characteristics" in Archives of Biological Sciences, 72, no. 1 (2020):31-36,
https://doi.org/10.2298/ABS191004063T . .